Abstract. The sources of TSH, which was excessively released by sulpiride (dopamine D2 receptor antagonist), were studied in 15 female patients with PRL-secreting adenoma (18-43 years). Sequential 3-day administration of sulpiride (100 mg, im) was given to 12 patients with prolactinoma and 6 normal female subjects (19) (20) (21) (22) (23) (24) 
It is well known that patients with prolactin-secreting adenoma (prolactinoma) often show rapid and exaggerated TSH responses to administration of dopamine antagonists (1) (2) (3) . In humans, adminis¬ tration of exogenous dopamine agonists inhibits TSH secretion and administration of dopamine an¬ tagonists stimulates TSH secretion in normal sub¬ jects and primary hypothyroid patients (3, (5) (6) (7) . Therefore, it is possible that hypothalamic dopamine exerts an inhibitory effect on TSH secretion.
The degree of TSH response to dopamine antag¬ onists would reflect the degree of hypothalamic do¬ pamine inhibition on thyrotropes (1, 8) . For these reasons, pituitary portal dopamine concentration in patients with prolactinoma is considered to be elevated by the positive feedback effect of PRL on hypothalamic dopamine neurons (1, 2, 8, 9) , al¬ though reduced hypothalamic dopaminergic tone was previously inferred (10, 11) . At (9), and 2. TSH responses to do¬ pamine antagonists are considered to be markedly increased when dopamine inhibition on thyro¬ tropes is much greater (1, 8) .
As for the underlying loss of dopamine inhibi¬ tion of PRL release, namely the sustained hyperprolactinemia and reduced PRL responsiveness to dopamine antagonism, a hypothalamic dopaminer¬ gic defect has been suggested (10, 11) . However, our data support the possibility that tumour lactotropes in these patients are insensitive to dopami¬ nergic inhibition (12, 13) . It seems that defective dopaminergic inhibition on tumour lactotropes will further stimulate the tuberoinfundibular dopa- Plasma PRL levels in normal subjects were sig¬ nificantly elevated even 24 hours after the sulpiride injection, as was reported previously (14, 15 (18) (19) (20) . In pituitary cells, it takes about 30 min from stimulus to mRNA production (20, 21) , and it takes about 60 min for the hormone secre¬ tion through gene transcriptional and transladonal processes (e.g. through new hormone synthesis) (22) . The (21, (23) (24) (25) , although multiple transduction mechanisms for the dopamine action must also be considered (26, 27) . In contrast, TRH mainly stimulates TSH and PRL release through the phosphatidylinositol system (21, 22, 28 (29, 30) . There¬ fore, it is possible that sulpiride and TRH stimu¬ lated the cAMP-protein kinase A system and phos¬ phatidylinositol system, respectively, and these second messenger systems cooperatively enhanced the TSH and PRL secretion in patients with pro¬ lactinoma.
In conclusion, TSH pools in thyrotropes may be increased in patients with prolactinoma, probably owing to the elevated hypothalamic dopaminergic inhibition, and there may be two readily releasable TSH and PRL pools, i.e. one dopamine-related and the other TRH-releated, in patients with prolacti¬ noma and normal subjects.
